Esposito F, et al. - The objective of this research was to inspect the fingolimod (FTY) effectiveness and to determine the baseline features linked with disease activity in a large Italian cohort of Relapsing–Remitting (RR) multiple sclerosis (MS) patients. During routine clinical practice and in the case of patients switching from natalizumab (NTZ) treatment, FTY effectiveness was affirmed. Data revealed that baseline parameters of inflammatory activity served as the most pivotal prognostic factors for mid-term disease reactivation also during second-line treatment with FTY. This, in turn, aided in determining how to select therapies towards a more personalized management.